Envisia Therapeutics To Present New Data At ARVO 2017 Annual Meeting

Company to Deliver Seven Data Presentations at World's Largest International Ophthalmology Gathering

News provided by

May 05, 2017, 08:15 ET

RESEARCH TRIANGLE PARK, N.C., May 5, 2017 /PRNewswire/ -- Envisia Therapeutics today announced that the Company will present new data for its next generation product candidate, ENV515 for glaucoma, as well as new data from its back of the eye programs, at the Association for Research in Vision and Ophthalmology's (ARVO) Annual Meeting being held May 7-11, 2017 in Baltimore, MD.

"We are very proud of the broad presence that we have at the ARVO 2017 Annual Meeting and are eager to share the progress we have made in leveraging the PRINT® platform to advance a promising pipeline of potentially transformative products in ophthalmology," said Benjamin Yerxa, PhD, President of Envisia Therapeutics. "ARVO continues to be the preeminent venue for scientific exchange in ophthalmology and we are very pleased to be able to present such a comprehensive array of data from our pipeline programs at this world renowned meeting."

Envisia's Senior Vice President of Development, Tomas Navratil, PhD, will co-chair a Special Interest Group symposium entitled Highlighting Successful Technologies in Sustained Drug Delivery in Ophthalmology: New Polymer Science and Particle Engineering Platforms that Drive Future Promising Extended Release Therapies and will present Utilizing Nano, Meso and Micro Particle Engineering to Formulate and Develop Extended Release Therapies for Glaucoma and DME: From Conceptual Designs to Clinical Proof of Concepts on Wednesday May 10^th from 1-2:30pm in Room 321.

Details related to Envisia's other presentations at ARVO are as follows:

Sunday, May 7, 2017

Extended Release Aflibercept with Sustained Vitreous Concentration in Non-Human Primates from Biodegradable Hydrogel Implants

Lead Author: Gary Owens
Posterboard No. A0275, Poster Session: AMD and Anti-VEGF Therapy, 1:30pm- 3:15pm

A 12-Month Study of the Effect of ENV515 (Travoprost) Intracameral Implant on Intraocular Pressure in Beagle Dogs

Lead Author: RiLee Robeson
Posterboard No. B0360, Poster Session: Intraocular pressure; aqueous humor dynamics, 3:15pm- 5:00pm

Monday, May 8, 2017

Extended PGA Delivery Results in Significant Drug Sparing Compared to Topical PGAs and Achieves Sustained IOP Lowering for 11 Months without Any Loss of Efficacy

Lead Author: Tomas Navratil, PhD
Posterboard No. A0169, Poster Session: Clinical Trials and Drug Studies I, 3:45pm-5:30pm

Interim Analysis of Low Dose ENV515 Travoprost XR with 11 Month Duration Followed by Dose Escalation and 28 Day Efficacy Evaluation of High Dose ENV515

Lead Author: Steven Mansberger, MD, MPH
Posterboard No. A0171, Poster Session: Clinical Trials and Drug Studies I, 3:45pm-5:30pm

Wednesday, May 10, 2017

In Vitro and In Vivo Sustained Release of Dexamethasone from Intravitreal Implants

Lead Author: Janet Tully
Posterboard No. B0111, Poster Session: Drug and Gene Therapy and Delivery, 8:30am- 10:15am

Development of an Intravitreal Extended Release Implant for the Treatment of Diabetic Macular Edema

Lead Author: Stuart Williams, PhD
Posterboard No. B0070, Poster Session: Drug Delivery I, 11:00am-12:45pm

In Vitro Sustained Release of Tyrosine Kinase Inhibitors from Biodegradable PRINT Implants

Lead Author: Melissa Sandahl
Posterboard No. B0071, Poster Session: Drug Delivery I, 11:00am-12:45pm

ARVO is globally recognized and respected as a leading provider of quality content and research in ophthalmology, and the annual meeting is the industry's largest gathering of eye and vision researchers in the world. The theme of the ARVO 2017 Annual Meeting is Global Connections in Vision Research.

ABOUT ENVISIA THERAPEUTICS™

Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is currently conducting a phase 2 clinical trial to investigate the safety and tolerability of ENV515 in patients with glaucoma. Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.

SOURCE Envisia Therapeutics